Table 1 Baseline Characteristics and Outcome Measures of Stroke Patients Receiving Different levels of Albumin in Serum.
Low level of albumin group (n = 65) | Normal level of albumin group (n = 363) | P Value | |
|---|---|---|---|
Age, y, median (IQR) | 66 (59–73) | 61 (53–67) | 0.002* |
Male sex, n(%) | 43 (66.2) | 273 (75.2) | 0.13 |
Medical history | |||
Hypertension, n(%) | 246 (67.8) | 37 (59.7) | 0.21 |
Diabetes mellitus, n(%) | 117 (32.2) | 20 (30.8) | 0.82 |
Atrial Fibrillation, n(%) | 46 (12.7) | 8 (12.9) | 0.96 |
Coronary artery disease, n(%) | 64 (17.6) | 12 (19.4) | 0.74 |
Current Smoking, n(%) | 92 (25.4) | 12 (19.4) | 0.31 |
Current Alcoholism, n(%) | 44 (12.2) | 9 (14.5) | 0.61 |
Previous stroke, n(%) | 92 (25.4) | 12 (19.4) | 0.31 |
OCSP | 0.916 | ||
LACI, n(%) | 14 (25.9) | 97 (27.2) | -- |
TACI, n(%) | 7 (13.0) | 35 (9.8) | -- |
PACI, n(%) | 23 (42.6) | 158 (44.4) | -- |
POCI, n(%) | 10 (13.2) | 66 (18.5) | -- |
Laboratory measures | |||
Glucose, mmol/L, median (IQR) | 5.69 (4.95–8.02) | 5.75 (4.97–7.26) | 1.00 |
LDL-cholesterol, mmol/L, median (IQR) | 2.46 (1.94–3.02) | 2.74 (2.21–3.25) | 0.06 |
INR, Median (IQR) | 1.06 (1.02–1.12) | 1.04 (0.98–1.1) | 0.014* |
Anticoagulation and statins therapy before admisson | |||
antiplatelet drugs, n(%) | 44 (12.2) | 9 (14.5) | 0.61 |
anticoagulants, n(%) | 4 (1.1) | 0 (0) | 1.00 |
statins, n(%) | 4 (6.6) | 33 (3.1) | 0.67 |
Previous use of antihypertensive drugs, n(%) | 24 (39.3) | 132 (36.5) | 0.67 |
Antidiabetic therapy before enrollment, n(%) | 15 (24.2) | 75 (20.8) | 0.54 |
Antiplatelet therapy after admission | |||
Aspirin 100 mg/d, n(%) | 16 (29.6) | 131 (38.2) | 0.23 |
Clopidogrel 75 mg/d, n(%) | 12 (19.0) | 48 (13.3) | 0.23 |
Aspirin 100 mg/d + Clopidogrel 75 mg/d, n(%) | 21 (38.9) | 119 (34.7) | 0.55 |
Warfarin, n(%) | 0 (0) | 16 (4.5) | 0.22 |
Statins | |||
Rosuvastatin, n(%) | 9 (16.7) | 20 (5.9) | 0.019 |
Atorvastatin, n(%) | 37 (56.9) | 290 (79.9) | < 0.001 |
Antihypertensive drugs, n(%) | 8 (11.1) | 64 (18.9) | 0.72 |
Antidiabetic drugs, n(%) | 7 (10.8) | 43 (11.8) | 0.89 |
NIHSS on admission, median (IQR) | 5 (3–11) | 5 (3–10) | 0.89 |
DNT, min, median (IQR) | 55.5 (42–100) | 54.5 (43–101) | 1.00 |
ONT, min, median (IQR) | 182.5 (125.75–255.75) | 194 (140–254) | 0.54 |
Treatment in extent time-window 3–4.5 h, n(%) | 13 (21.0) | 139 (41.4) | 0.002* |
Systolic blood pressure, mmHg, median (IQR) | 140 (125–165) | 140 (137–161) | 0.24 |
Hemorrhagic transformation, n(%) | 9 (15.3) | 15 (4.2) | 0.002* |
Symptom intracranial hemorrhage, n(%) | 5 (6.2) | 4 (1.4) | 0.03* |
NIHSS at 24 h, median (IQR) | 3 (1–8) | 3 (1–9) | 0.90 |
NIHSS at 7 days, (median (IQR) | 2 (0–5) | 1.5 (0–5.75) | 0.53 |
Barthel Index at 7 days, median (IQR) | 75 (50.0–90.0) | 60.0 (25.0–87.5) | 0.061 |
mRS at 7 days, median (IQR) | 2 (1–4) | 2 (0–4) | 0.84 |
mRS at 90 days, median (IQR) | 2 (0–3) | 1 (0–3) | 0.698 |
favorable outcome at 90 days, n(%) | 33 (64.7) | 195 (67.5) | 0.698 |
